D.H.E. 45

Dihydroergotamine Mesylate

By Valeant Pharmaceuticals North America | Last revised: 9 August 2012

D.H.E. 45 (dihydroergotamine mesylate) Injection USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. CONTRAINDICATIONS: There have been a few reports of serious…

Dacarbazine

Dacarbazine

By Teva Parenteral Medicines, Inc | Last revised: 9 October 2009

Dacarbazine for injection is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine for injection is also indicated for Hodgkin’s disease as a secondary-line therapy when used in combination with other effective agents…

Dacarbazine

Dacarbazine

By Bedford Laboratories | Last revised: 5 May 2010

Dacarbazine is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. CONTRAINDICATIONS:…

Dacarbazine

DACARBAZINE

By Hospira Worldwide, Inc. | Last revised: 27 September 2011

Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition. Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents…

Dacarbazine

DACARBAZINE

By APP Pharmaceuticals, LLC | Last revised: 4 September 2012

Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition. Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents…